Ancona-Vadillo AE

Idioma: Inglés [English version]
Referencias bibliográficas: 11
Paginas: s204-208
Archivo PDF: 296.58 Kb.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Cho L, Davis M, Elgendy I, Epps K, Lindley KJ, Mehta PK et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC state-of-the-art review. J Am Coll Cardiol. 2020; 75 (20): 2602-2618.

2. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41 (1): 111-188.

3. Freedman DS, Bowman BA, Otvos JD, Srinivasan SR, Berenson GS. Levels and correlates of LDL and VLDL particle sizes among children: the Bogalusa heart study. Atherosclerosis. 2000; 152 (2): 441-449.

4. Phan BA, Toth PP. Dyslipidemia in women: etiology and management. Int J Womens Health. 2014; 6: 185-194.

5. Feitosa ACR, Barreto LT, Silva IMD, Silva FFD, Feitosa GSF. Impact of the use of different diagnostic criteria in the prevalence of dyslipidemia in pregnant women. Arq Bras Cardiol. 2017; 109 (1): 30-38.

6. Pinkas J, Gujski M, Wierzbinska-St?pniak A, Owoc A, Bojar I. The polymorphism of estrogen receptor α is important for metabolic consequences associated with menopause. Endokrynol Pol. 2016; 67 (6): 608-614.

7. Lewandowski KC, P?usajska J, Horzelski W, Lewi?ski A. Prevalence of dyslipidaemia and pre-diabetes among women with polycystic ovary syndrome (PCOS): do we overestimate cardiovascular risk? Horm Metab Res. 2019; 51 (8): 539-545.

8. Guo Q, Zhou S, Feng X, Yang J, Qiao J, Zhao Y et al. The sensibility of the new blood lipid indicator--atherogenic index of plasma (AIP) in menopausal women with coronary artery disease. Lipids Health Dis. 2020; 19 (1): 27.

9. Ajufo E, Rader DJ. Recent advances in the pharmacological management of hypercholesterolaemia. Lancet Diabetes Endocrinol. 2016; 4 (5): 436-46.

10. Welty FK, Lewis SJ, Friday KE, Cain VA, Anzalone DA. A comparison of statin therapies in hypercholesterolemia in women: a subgroup analysis of the STELLAR study. J Womens Health (Larchmt). 2016; 25 (1): 50-56.

11. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010; 121 (9): 1069-1077.